Quick Answer
60 DEGREES PHARMACEUTICALS, INC. reported Total Revenue of $1.01 million for fiscal year 2025.
60 DEGREES PHARMACEUTICALS, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | $1.01M +65.5% |
$607.6K +139.6% |
$253.6K +13.6% |
$223.2K | — |
| Net Income | -$7.37M +7.3% |
-$7.95M -111.0% |
-$3.77M +39.1% |
-$6.18M | — |
| Diluted EPS | -$11.73 +84.2% |
-$74.17 -25.3% |
-$59.18 -2167.4% |
-$2.61 | — |
| Total Assets | $5.37M -6.8% |
$5.76M -26.0% |
$7.78M +500.0% |
$1.30M | — |
| Cash and Equivalents | $1.51M -9.0% |
$1.66M -22.6% |
$2.14M | — | — |
| Stockholders Equity | $3.46M -14.2% |
$4.04M -17.1% |
$4.87M +120.7% |
-$23.58M -29.9% |
-$18.15M |
| R&D Expense | $2.11M -57.8% |
$4.99M +620.8% |
$691.8K +31.6% |
$525.6K | — |
| Operating Income | -$7.76M +20.1% |
-$9.72M -88.5% |
-$5.15M -194.5% |
-$1.75M | — |
| Gross Profit | $223.8K +0.4% |
$222.8K +200.8% |
-$221.0K -5.6% |
-$209.2K | — |
| Shares Outstanding | 1.47M -93.1% |
21.22M +21810.8% |
96,847 | — | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $437.6K | +223.4% | +333.6% |
| Net Income | September 30, 2025 | -$2.32M | -7.2% | -33.6% |
| Diluted EPS | September 30, 2025 | -$0.66 | +77.4% | +47.2% |
| Total Assets | September 30, 2025 | $6.69M | -9.9% | +60.0% |
| Cash and Equivalents | September 30, 2025 | $4.12M | — | +109.2% |
| Stockholders Equity | September 30, 2025 | $4.43M | -26.6% | +82.4% |
| R&D Expense | September 30, 2025 | $809.8K | -13.9% | +224.1% |
| Operating Income | September 30, 2025 | -$2.33M | -9.8% | -44.9% |
| Gross Profit | September 30, 2025 | -$100.1K | -524.0% | -296.7% |
| Shares Outstanding | September 30, 2025 | 4.10M | +120.4% | +178.7% |
- 60 DEGREES PHARMACEUTICALS, INC. reported Total Revenue of $1.01 million for fiscal year 2025.
- 60 DEGREES PHARMACEUTICALS, INC. showed an increase of +65.5% in Total Revenue compared to the prior fiscal year.
- 60 DEGREES PHARMACEUTICALS, INC. reported Net Income of -$7.37 million for fiscal year 2025.
- 60 DEGREES PHARMACEUTICALS, INC. showed an increase of +7.3% in Net Income compared to the prior fiscal year.
- 60 DEGREES PHARMACEUTICALS, INC. reported Diluted EPS of $11.73 per share (loss) for fiscal year 2025.
- 60 DEGREES PHARMACEUTICALS, INC. showed an increase of +84.2% in Diluted EPS compared to the prior fiscal year.
- 60 DEGREES PHARMACEUTICALS, INC. reported Total Assets of $5.37 million for fiscal year 2025.
- 60 DEGREES PHARMACEUTICALS, INC. showed a decrease of -6.8% in Total Assets compared to the prior fiscal year.
- 60 DEGREES PHARMACEUTICALS, INC. reported Cash and Equivalents of $1.51 million for fiscal year 2025.
- 60 DEGREES PHARMACEUTICALS, INC. showed a decrease of -9.0% in Cash and Equivalents compared to the prior fiscal year.
- 60 DEGREES PHARMACEUTICALS, INC. reported Stockholders Equity of $3.46 million for fiscal year 2025.
- 60 DEGREES PHARMACEUTICALS, INC. showed a decrease of -14.2% in Stockholders Equity compared to the prior fiscal year.
- 60 DEGREES PHARMACEUTICALS, INC. reported R&D Expense of $2.11 million for fiscal year 2025.
- 60 DEGREES PHARMACEUTICALS, INC. showed a decrease of -57.8% in R&D Expense compared to the prior fiscal year.
- 60 DEGREES PHARMACEUTICALS, INC. reported Operating Income of -$7.76 million for fiscal year 2025.
- 60 DEGREES PHARMACEUTICALS, INC. showed an increase of +20.1% in Operating Income compared to the prior fiscal year.
- 60 DEGREES PHARMACEUTICALS, INC. reported Gross Profit of $223.8 thousand for fiscal year 2025.
- 60 DEGREES PHARMACEUTICALS, INC. showed an increase of +0.4% in Gross Profit compared to the prior fiscal year.
- 60 DEGREES PHARMACEUTICALS, INC. reported Shares Outstanding of 1.16 million shares for fiscal year 2025.
- 60 DEGREES PHARMACEUTICALS, INC. showed a decrease of -21.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: